Safety Study of BIIB033 in Subjects With Multiple Sclerosis

Multiple Sclerosis Clinical Trial

Official title:

A Randomized, Blinded, Placebo-Controlled, Serial-Cohort, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Multiple Sclerosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01244139
• Other study ID #: 215MS101
• Status: Completed
• Phase: Phase 1
• First received: November 18, 2010
• Last updated: January 5, 2017
• Start date: October 2010
• Est. completion date: April 2012

Study information

• Verified date: January 2017
• Source: Biogen
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The main purpose of the study is to evaluate the safety, tolerability, and pharmacokinetic profile of two intravenous infusions of BIIB033 administered two weeks apart in subjects with MS.

Approximately 42 MS subjects are planned to be enrolled in the study in 7 separate groups (i.e., 6 subjects per group). Each subsequent group will be administered a higher dose of BIIB033. Before a higher dose group is allowed to start, a Drug Safety Review Committee will review all safety data from previous groups enrolled, as well as data from another study where BIIB033 is being administered to healthy volunteers (215HV101).

Description:

BIIB033 is a protein that acts on certain types of brain cells by blocking the function of another protein called LINGO-1. It is believed that LINGO-1 is one of the reasons why nerves in the brain of patients with MS do not repair well. It is thought BIIB033 may improve MS by repairing damaged nerve tissue. LINGO-1 is also present in the brain of healthy people.

Subjects will take part in the 215MS101 study for up to 28 weeks. This includes a 4-week screening period, a 2 week treatment period in which 2 doses of BIIB033 are given, and a post-dosing safety follow up period of up to 22 weeks (depending on dose cohort).

The study tests vary at each of the individual visits and may include:

medical history evaluation, height and weight assessment, physical examination, neurological examination, vital signs assessment (pulse, respiratory rate, blood pressure, and temperature), MS performance score, electrocardiogram, cardiac monitoring, routine blood and urine tests, drug concentration testing of the blood, hepatitis and HIV tests, blood clotting tests, brain MRI scan, lumbar puncture, and drugs of abuse screen and pregnancy test.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 47
• Est. completion date: April 2012
• Est. primary completion date: April 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Give informed consnet

• Aged 18 to 60 years

• Have relapsing remitting MS or secondary progressive MS

• EDSS score of 1 to 6 inclusive

• Body mass index of 18 to 30 kg/m2

• Commitment to use effective contraception 6 months after last dose of study drug Treatment with any interferon beta or glatiramer acetate is allowed to continue during the study as long as the initiation of treatment was at least 3 months and the dose is stable.

Key Exclusion Criteria:

• Primary progressive MS

• Any significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, allergic or anaphylactic reactions or other major disease

• Clinically significant lab value at screening outside of normal range

• Clinically significant ECG abnormality

• Contraindication to MRI scans or lumbar punctures

• Plans to undergo elective surgery during study

• An MS relapse that has not resolved within 30 days before screening

• History or postive test result for Hepatitis B, C and HIV

• Serious infections within 3 months prior to Day -1

• Treatment with MS medication within 12 months prior to Day -1: natalizumab, daclizumab, azathioprine, methotrexate, iV immunoglobulin, plasmapheresis or mycophenolate motefil

• Prior treatment with total lymphoid irradiation, T cell or T-cell receptor vaccination, alemtuzumab, mitoxantone, cyclophosphamide, rituximab, fingolimod.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)

Related Conditions & MeSH terms

• Multiple Sclerosis
• Multiple Sclerosis, Relapsing-Remitting
• Relapsing-Remitting Multiple Sclerosis
• Sclerosis

Intervention

Drug:
• BIIB033
IV infusion of 0.3, 1, 3, 10, 30, 60 or 100 mg/kg
• Placebo
IV infusion dummy drug

Locations

Country	Name	City	State
United States	Research Site	Centennial	Colorado

Sponsors (1)

Lead Sponsor	Collaborator
Biogen

Country where clinical trial is conducted

United States, 

References & Publications (1)

Tran JQ, Rana J, Barkhof F, Melamed I, Gevorkyan H, Wattjes MP, de Jong R, Brosofsky K, Ray S, Xu L, Zhao J, Parr E, Cadavid D. Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. Neurol Neuroimmunol Neuroinflamm. 2014 Aug 21;1(2):e18. doi: 10.1212/NXI.0000000000000018. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluate safety and tolerability profile of two IV infusions of BIIB033 in subjects with MS		For duration of study / 6 months	Yes
Primary	Identify incidence and types of adverse events		For duration of study / 6 months	Yes
Primary	The incidence of serious adverse events		For duration of study / 6 months	Yes
Primary	Changes from baseline in clinical lab assessments and vital signs		For duration of study / 6 months	Yes
Primary	Changes form baseline in other safety measures: physical and neurological examinations, brain MRIs, and ECGs		For duration of study / 6 months	Yes
Secondary	Assess the repeat-dose serum PK profile of BIIB033		For duration of study / 6 months	Yes
Secondary	Assess the repeat-dose immunogenicity of BIIB033		For duration of study / 6 months	Yes
Secondary	Measure the concentration of BIIB033 in the cerebrospinal fluid		At specified timepoints in the study	Yes
Secondary	Explore potential biomarkers of BIIB033 activity in the periphery and in the central nervous system		At specified timepoints in the study	No